[go: up one dir, main page]

WO2009013614A3 - Marker gene - Google Patents

Marker gene Download PDF

Info

Publication number
WO2009013614A3
WO2009013614A3 PCT/IB2008/001957 IB2008001957W WO2009013614A3 WO 2009013614 A3 WO2009013614 A3 WO 2009013614A3 IB 2008001957 W IB2008001957 W IB 2008001957W WO 2009013614 A3 WO2009013614 A3 WO 2009013614A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
bmi
mrna
protein
cml
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/001957
Other languages
French (fr)
Other versions
WO2009013614A2 (en
Inventor
Mohamad Mohty
Agnes Siew Mee Yong
Melo Junla Vaz De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Publication of WO2009013614A2 publication Critical patent/WO2009013614A2/en
Publication of WO2009013614A3 publication Critical patent/WO2009013614A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method of aiding in prognosing chronic myeloid leukemia (CML) by determining the level of BMI-1 mRNA or protein in a sample provided from a patient. A method of increasing the life expectancy of a patient in the chronic phase of chronic myeloid leukemia comprising administering a compound which is capable of reducing the expression or function of BMI-1 mRNA or protein in the patient. A method of aiding in assessing the suitability of a patient with CML to receive an allogeneic stem cell transplant, or such a transplant after enhanced prophylaxis for graft versus host disease, comprising determining the level of BMI-1 mRNA or protein in a sample provided from a patient. Associated methods of treating a patient, depending on the outcome of such assessment are provided
PCT/IB2008/001957 2007-07-26 2008-07-25 Marker gene Ceased WO2009013614A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0714573A GB0714573D0 (en) 2007-07-26 2007-07-26 Marker gene
GB0714573.3 2007-07-26
US98745507P 2007-11-13 2007-11-13
US60/987,455 2007-11-13

Publications (2)

Publication Number Publication Date
WO2009013614A2 WO2009013614A2 (en) 2009-01-29
WO2009013614A3 true WO2009013614A3 (en) 2009-05-07

Family

ID=38512906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/001957 Ceased WO2009013614A2 (en) 2007-07-26 2008-07-25 Marker gene

Country Status (2)

Country Link
GB (1) GB0714573D0 (en)
WO (1) WO2009013614A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009009672A1 (en) * 2009-02-19 2010-09-02 Johannes-Gutenberg-Universität Mainz Regulatory nucleic acid of a human proteinase 3 variant
MX337666B (en) * 2009-10-20 2016-03-14 Nestec Sa Proximity-mediated assays for detecting oncogenic fusion proteins.
HK1215032A1 (en) 2012-11-21 2016-08-12 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
AU2013399092A1 (en) 2013-08-30 2016-03-17 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
KR101820572B1 (en) * 2015-08-12 2018-01-19 가톨릭대학교 산학협력단 Method for providing the information for chronic myeloid leukemia
US10253371B2 (en) 2016-08-29 2019-04-09 National Guard Health Affairs Method of treating leukemia based on gene expression of clock genes
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHOWDHURY M ET AL: "Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K MAY 2007, vol. 21, no. 5, May 2007 (2007-05-01), pages 1116 - 1122, XP002506316, ISSN: 0887-6924 *
MENG XIU-XIANG ET AL: "Construction of antisense Bmi-1 expression plasmid and its inhibitory effect on K562 cells proliferation.", CHINESE MEDICAL JOURNAL 20 AUG 2005, vol. 118, no. 16, 20 August 2005 (2005-08-20), pages 1346 - 1350, XP002506314, ISSN: 0366-6999 *
MERKEROVA MICHAELA ET AL: "Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 48, no. 4, 1 April 2007 (2007-04-01), pages 793 - 801, XP009109369, ISSN: 1042-8194 *
MOHTY MOHAMAD ET AL: "The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.", BLOOD 1 JUL 2007, vol. 110, no. 1, 1 July 2007 (2007-07-01), pages 380 - 383, XP002506313, ISSN: 0006-4971 *
YONG AGNES S M ET AL: "Hematopoietic stem cells and primitive progenitors express leukemia associated antigens that may be targets for graft-versus-leukemia effect or for vaccine-based immunotherapy in chronic myeloid leukemia.", BLOOD, vol. 108, no. 11, Part 1, November 2006 (2006-11-01), & 48TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 09 -12, 2006, pages 602A - 603A, XP002506315, ISSN: 0006-4971 *
YONG AGNES S M ET AL: "Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.", BLOOD 1 JAN 2006, vol. 107, no. 1, 1 January 2006 (2006-01-01), pages 205 - 212, XP002506317, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2009013614A2 (en) 2009-01-29
GB0714573D0 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
WO2009013614A3 (en) Marker gene
Ge et al. HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF‐1 expression and activates W nt pathway
Fang et al. Cancer stem cells and epithelial–mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches
Kasajima et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours
Arai et al. Regulation of NCAPG by miR‐99a‐3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC
Tanaka et al. Clinical impact of serum exosomal microRNA‐21 as a clinical biomarker in human esophageal squamous cell carcinoma
Ghosh et al. Identification of key players for colorectal cancer metastasis by iTRAQ quantitative proteomics profiling of isogenic SW480 and SW620 cell lines
Xiao et al. MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis
MX2009002936A (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors.
NZ593228A (en) Gene expression markers (inhba) for colorectal cancer prognosis
EA201100452A1 (en) TREATMENT OF INFLAMMATORY CONDITIONS
WO2007085497A8 (en) Markers for the prediction of outcome of anthracycline treatment
Xie et al. miRNA-124 down-regulates SOX8 expression and suppresses cell proliferation in non-small cell lung cancer
Chen et al. Up-regulated miR-548k promotes esophageal squamous cell carcinoma progression via targeting long noncoding RNA-LET
Wei et al. Signal Peptide Peptidase, Encoded by HM 13, Contributes to Tumor Progression by Affecting EGFR v III Secretion Profiles in Glioblastoma
Zhao et al. LncRNA ZEB1‐AS1 down‐regulation suppresses the proliferation and invasion by inhibiting ZEB1 expression in oesophageal squamous cell carcinoma
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
Li et al. hMOF (human males absent on the first), an oncogenic protein of human oral tongue squamous cell carcinoma, targeting EZH2 (enhancer of zeste homolog 2)
WO2008115470A3 (en) Hox-gene expression as a biomarker for igf-1r therapeutics
Zhao et al. GOLPH3 promotes angiogenesis of lung adenocarcinoma by regulating the Wnt/β-catenin signaling pathway
Xuan et al. MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition.
Gu et al. Clinic significance of microRNA‐99a expression in human lung adenocarcinoma
Yan et al. Tumor‐associated macrophages‐derived exo‐let‐7a promotes osteosarcoma metastasis via targeting C15orf41 in osteosarcoma
Yamashita et al. Activation of the aryl hydrocarbon receptor by 3-methylcholanthrene, but not by indirubin, suppresses mammosphere formation via downregulation of CDC20 expression in breast cancer cells
Rashid et al. Elucidating the role of miRNA-326 modulating hedgehog signaling in pancreatic carcinoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788937

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08788937

Country of ref document: EP

Kind code of ref document: A2